Evidence map›Paper›PMID 23914149›Full record

ArticleCurrent colorectal cancer reports2012

The RNA-Binding Protein Musashi1: A Major Player in Intestinal Epithelium Renewal and Colon Cancer Development.

Michelina Plateroti, Patricia Rosa de Araujo, Acarizia Eduardo da Silva, Luiz O F Penalva

Abstract read
In one paragraph

Article in Current colorectal cancer reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Expression of Musashi-1 Increases in Bone Healing.International journal of molecular sciences · 2021
    Article
  3. Interplay among p21Scientific reports · 2020
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Michelina PlaterotiCentre de Génétique et de Physiologie Moléculaire et Cellulaire, Université Claude Bernard Lyon 1, France. 16 Rue Raphael Dubois, 69622 Villeurbanne, Cedex France.
Patricia Rosa de Araujo
Acarizia Eduardo da Silva
Luiz O F Penalva
Cancer Research Institute · USThe University of Texas Health Science Center at San Antonio · USUniversité Claude Bernard Lyon 1 · FR

Funding

Computational Methods for Deep Sequencing Based RBP Binding Motif CharacterizatioR01HG006015 · NHGRI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI PENALVA, LUIZ OTAVIO, SMITH, ANDREW DAVID · 2011 to 2017
$2.6M
NHGRI NIH HHS R01 HG006015
6 · The paper itself

Abstract

Aberrant gene expression is the cause and the consequence of tumorigenesis. A major component of gene expression is translation regulation; a process whose main players are RNA-binding-proteins (RBPs). More than 800 RBPs have been identified in the human genome and several of them have been shown to control gene networks associated with relevant cancer processes. A more systematic characterization of RBPs starts to reveal that similar to transcription factors, they can function as tumor suppressors or oncogenes. A relevant example is Musashi1 (Msi1), which is emerging as a critical regulator of tumorigenesis in multiple cancer types, including colon cancer. Msi1 is a stem marker in several tissues and is critical in maintaining the balance between self-renewal and differentiation. However, a boost in Msi1 expression can most likely lead cells towards an oncogenic pathway. In this article, we discuss the parallels between Msi1 function in normal renewal of intestinal epithelium and in colon cancer.

Indexed as

Colon cancerMusashi1RNA-binding proteinsTranslation regulation

Identifiers

PMID23914149
PMCPMC3728701
OpenAlexW2004476210

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.